Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

U.S. rolls out COVID vaccine for tots

Published 06/18/2022, 01:42 PM
Updated 06/18/2022, 08:20 PM
© Reuters. FILE PHOTO: Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
PFE
-
WMT
-
CVS
-
US90274J5618=UBSS
-
MRNA
-

By Makini Brice

WASHINGTON (Reuters) -The U.S. Centers for Disease Control and Prevention on Saturday recommended COVID-19 vaccines for children as young as six months, allowing a nationwide rollout to start next week.

The CDC's move came after a panel of advisers to the institution voted earlier on Saturday to recommend COVID-19 vaccines for those children.

"We know millions of parents and caregivers are eager to get their young children vaccinated, and with today's decision, they can," said Rochelle Walensky, the CDC director, in a statement.

The U.S. Food and Drug Administration on Friday authorized Moderna (NASDAQ:MRNA) Inc's shot for children aged six months to five years, and Pfizer-BioNTech's vaccine for children aged six months to four years. Pfizer (NYSE:PFE)'s vaccine is already authorized for children over the age of five.

"This infection kills children and we have an opportunity to prevent that," Beth Bell, one of the doctors on the advisory panel, said following the vote. "Here is an opportunity to prevent a known risk."

Education Secretary Miguel Cardona said in a statement the move was a "historic milestone."

President Joe Biden's administration plans to roll out the vaccines to the under-five age groups as early as next week.

"This coming week, parents will be able to start scheduling appointments at places like pediatricians’ offices, children’s hospitals, and pharmacies," Biden said in a statement on Saturday.

"Appointments will ramp up as more doses are shipped out, and in the coming weeks, every parent who wants a vaccine will be able to get one. As the vaccination program ramps up, Vaccines.gov will be live next week with vaccine availability and appointments increasing throughout the week."

While many parents in the United States are eager to vaccinate their children, it is unclear how strong demand will be for the shots. The Pfizer-BioNTech vaccine was authorized for children aged 5 to 11 in October, but only about 29% of that group is so far fully vaccinated, federal data shows.

CVS Health Corp (NYSE:CVS) plans to provide vaccines to children aged 18 months and older while Rite Aid (NYSE:RAD) Corp and Walmart (NYSE:WMT) Inc plan to offer these shots for kids who are at least three years old. Infants are traditionally vaccinated at a doctor's office.

Public health officials have been pushing for childhood vaccinations ahead of the new school year as they hope shots for the age group will help prevent hospitalizations and deaths if COVID-19 cases rise again.

© Reuters. Vials of the Pfizer-BioNTech coronavirus disease (COVID-19) pediatric vaccine are pictured in Lansdale, Pennsylvania, U.S., December 5, 2021. REUTERS/Hannah Beier

COVID-19 is generally more mild in children. Still, since March 2020 it has been the fifth leading cause of deaths in children aged 1-4 and the fourth leading cause of death in children younger than one, according to the CDC.

The CDC advisers will meet again next week to consider whether to back use of the Moderna vaccine for children and adolescents aged 6-17. There has been some concern about the rate of rare cases of heart inflammation in teenage boys and young men from the Moderna vaccine, and the advisers are expected to consider that data.

(Additional Reporting by Leroy Leo, Manas and Jaiveer Singh Shekhawat in Bengaluru; Editing by Paul Simao, Franklin Paul and Daniel Wallis)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.